Subcutaneous ancrod after operation for fractured hip--a dose-ranging and feasibility study.
We have conducted a dose-ranging and feasibility study of daily subcutaneous injections of ancrod (Arvin) as a potential antithrombotic method in 28 patients following operation for fractured neck of femur. Sustained, predictable fibrinogen depletion during the first post-operative week was induced by four different regimes. A total dose of 10 units/kg weight, given in divided doses starting on the day of operation, is suggested as a possible antithrombotic regime. Ancrod treatment produced a rise in fibrinogen/fibrin degradation products, prolongation of the thrombin clotting time, and a fall in plasminogen, plasma fibrinogen and corrected blood viscosity were observed in 14 control patients. Plasma fibrinogen was correlated with plasma viscosity and corrected blood viscosity. No adverse effects of treatment occurred. Subcutaneous ancrod appears to be a simple, safe, and feasible potential antithrombotic method, and merits trials of efficacy in the prevention of post-operative thromboembolism.
D000328:Adult; D000368:Aged; D000721:Ancrod / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D001809:Blood Viscosity; D004305:Dose-Response Relationship, Drug; D005260:Female; D005265:Femoral Neck Fractures / Q000188:drug therapy*; D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen; D006400:Hematocrit; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged
D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen; D000721:Ancrod